Please wait while the formulary information is being retrieved.
XRYLIDERM (LIDOCAINE/KINESIOLOGY TAPE)
- Postherpetic neuralgia
5 % topical kit
- Apply 1 patch by transdermal route once daily (may wear up to 12Hours.)
Postherpetic neuralgia
- Apply 1 patch by transdermal route once daily (may wear up to 12Hours.)
- Apply 2 patches by transdermal route once daily (may wear up to 12Hours.)
- Apply 1 patch by topical route once daily (may wear up to 12Hours.)
- Apply 2 patches by topical route once daily (may wear up to 12Hours.)
- Apply 3 patches by topical route once daily (may wear up to 12Hours.)
- Apply 3 patches by transdermal route once daily (may wear up to 12Hours.)
- None
Contraindicated
- None
Severe
Moderate
- None
- Large open wound
- Methemoglobinemia
Contraindicated
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart block
- Hemolytic anemia from PK and g6PD deficiencies
- Sepsis
- Shock
Severe
Moderate
- Disease of liver
- Respiratory depression
- Seizure disorder
XRYLIDERM (LIDOCAINE/KINESIOLOGY TAPE)
- Postherpetic neuralgia
- None
- None
More Frequent
Severe
Less Severe
- Angioedema
- Dermatitis due to topical drug
- Erythema
- Pruritus of skin
- Skin rash
- Stinging of skin
- Urticaria
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory insufficiency
- Anaphylaxis
- Bradycardia
- Cardiac arrhythmia
- CNS toxicity
- Cyanosis
- Drowsy
- Eyelid edema
- Headache disorder
- Hypotension
- Methemoglobinemia
- Respiratory depression
- Seizure disorder
- Tremor
- Unconsciousness
Less Severe
- Acute confusion
- Apprehension
- Blurred vision
- Dizziness
- Edema
- Euphoria
- Nervousness
- Sensation of cold
- Sensation of warmth
- Tinnitus
- Twitching
- Vomiting
Contraindicated
None
Severe Precaution
Lidocaine (Top)
Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
Management or Monitoring Precaution
Lidocaine (Top)
Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
- 180 Days – 13 Years
- Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
General | Excretion Potential | Effect on Infant | Notes |
No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Postherpetic neuralgia | |
B02.22 | Postherpetic trigeminal neuralgia |
B02.23 | Postherpetic polyneuropathy |
0-9 | A-Z |
---|---|
B02.22 | Postherpetic trigeminal neuralgia |
B02.23 | Postherpetic polyneuropathy |
Formulary Reference Tool